《大行報告》美銀證券重申京東(09618.HK)「買入」評級 目標價上調至406元
美銀證券發表報告指,京東(09618.HK)季績續見健康增長,主要來自低端城市新用戶增加,佔整體新用戶80%,並有更多成熟階層客戶,相信是因肺炎疫情推動。另外京東在奢侈品、糧油雜貨、家居裝飾、新鮮農產品、食物及飲品,及藥物與保健產品等類型的網上滲透率增加,客戶購買數量亦提升。京東對多個業務投資亦有助提升利潤率。
基於京東第三季收入增長、其他收入增加,及資本開支與稅務開支較低,該行上調京東2020年至2022年每股盈利預測各22%、22%及0.5%,目標價自386.1元上調至406元,重申「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.